The Clinical Characteristics And Prognosis Analysis Of Lung Adenocarcinoma With EGFR,ALK And BRAF Genes In Xinjiang Region

Objective:This study aimed to investigate the clinical characteristics and prognosis of EGFR,ALK and BRAF genes in patients with lung adenocarcinoma in Xinjiang region.Method:163 cases who completed EGFR or ALK gene test were selected for statistical analysis.Choosing 69 NSCLC patients to detect the mutation of BRAF by using immunocytochemistry.Taking the mutation-type and the wild-type to compare their clinicopathologic characteristics,and prognosis.Result:1)The mutation rates of EGFR,ALK,and BRAF were 34.9%,16.2%,and 4.3%.2)EGFR gene is significantly associated with gender(P<0.05).The mutation rate of ALK and BRAF had no significant difference with gender,age,smoking and degree of differentiation(P> 0.05).3)Median PFS and median OS were longer in patients with EGFR mutations and ALK mutation than those with negative mutations(P<0.05).There was no significant difference between BRAF gene mutation and wild-type with median PFS and median OS(P>0.05).Conclusion:The mutation rates of EGFR,ALK,and BRAF were 34.9%,16.2%,and 4.3%.Lung adenocarcinomas with EGFR and ALK mutations have a better prognosis.BRAF mutation has no clear effect on the effect of chemotherapy.